Sanofi inks 3rd COVID-19 vaccine production pact, this time helping Moderna with fill and finish work COVID test maker Innova picks up Los Angeles-based N95 outfit Experts: COVID's telehealth boom giving patients an 'overwhelming drive for self-empowerment' AstraZeneca's next COVID-19 vaccine headache? A lawsuit from the EU over supply shortcomings Hospital margins stay narrow, volume declines persist in Q1 2021: Kaufman Hall Emergent CEO sold more than $10 million in stock before scrapping J&J COVID-19 vaccine doses: report Johnson & Johnson's D.C. incubator opens for business with diversity at its core UPDATED Coronavirus tracker: HIMSS21 posts update on health, safety plans for August conference Regeneron CEO Schleifer, chief scientist Yancopoulos bag massive $270M payday Philips ups financial projections for the year despite double-digit drop in demand for connected care products COVID-19 tracker: U.S. to share supply of AstraZeneca vaccine; WHO to review Moderna shot for emergency listing Featured Story | By Kevin Dunleavy While Sanofi continues to try to develop two COVID-19 vaccine candidates, it is helping other companies produce their shots. On Monday the company announced it would produce COVID-19 vaccines for Moderna. The French drugmaker already has provided manufacturing for the Johnson & Johnson and Pfizer-BioNTech COVID-19 vaccines. read more |
| |
|---|
|
Top Stories By Conor Hale Innova Medical Group is settling in for the long haul with its acquisition of the personal protective equipment manufacturer Pacific PPE Corporation. read more By Paige Minemyer It's not a secret that COVID-19 has dramatically increased the demand for and interest in digital health. There is an "overwhelming drive for self-empowerment" that patients are now beginning to experience as they embrace virtual healthcare services, said Matthew Stoudt, co-founder and CEO of AppliedVR. Here's what else Stoudt and executives at Lyra Health and Hims & Hers had to say about where digital health is headed. read more By Noah Higgins-Dunn The European Commission confirmed on Monday that it's moved forward with legal proceedings against AstraZeneca for failing to deliver its promised supply of COVID-19 vaccines and for not having a "reliable" plan in place, a spokesperson told Reuters. read more By Dave Muoio Hospitals' mixed report card is still a major improvement over the pandemic's worst month, Kaufman Hall wrote in a new report. It's also likely a precursor to months of margin gains, though these won't eclipse pre-pandemic highs. read more By Noah Higgins-Dunn The chief of Emergent BioSolutions, Robert Kramer, sold more than $10 million in shares right before the company issued its financial results and news broke that it had to scrap millions of COVID-19 vaccine doses at its Baltimore plant, The Washington Post reports. The transaction was part of a pre-adopted trading plan. read more By Amirah Al Idrus The pandemic wasn’t going to slow JLABS down. Two years after announcing a new location, Johnson & Johnson’s incubator arm opened its doors in the nation’s capital on Monday, right on time. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner Regeneron chief Len Schleifer earned a whopping $135 million in 2020 as the company opted to give its top execs years of front-loaded equity awards. Meanwhile, chief scientist George Yancopoulos made $134.38 million for the year. read more By Andrea Park Philips posted a 9% year-over-year increase in overall sales growth for the first three months of the year, thanks in large part to an 11% jump in orders for its diagnostic and treatment products. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky The U.S. will begin sharing its supply of AstraZeneca's COVID-19 vaccine with other countries once the shot clears safety reviews by federal regulators, the Biden administration announced. The World Health Organization said it will begin reviewing Moderna's vaccine for emergency-use listing on Friday. And more headlines. read more |
